Wednesday, July 19, 2017 – Noon-1:30 p.m.Russell Senate Office Building, Room 485 – U.S. Capitol Hill
One of the most promising areas of cancer research is the field of immuno-oncology. Scientists are discovering new ways to arm a patient’s immune system so that it can attack cancer cells, and the result has been one of the most transformative approaches to cancer treatment that has ever entered the clinic.
For many patients, cancer immunotherapies are already providing life-saving results where other treatments had failed or were not viable. But realizing more breakthroughs in this area and broadening the scope of cancers that can be treated with immuno-oncology requires a sustained, federal investment in cancer research through the National Institutes of Health and the National Cancer Institute.
The American Association for Cancer Research and the Society for Immunotherapy of Cancer were pleased to host a briefing that highlighted exciting innovations being delivered through immuno-oncology, illustrated the hope that these advances are bringing to patients and noting the challenges that still need to be overcome so more patients can benefit from these revolutionary treatments.
Click here to download an informational flyer (PDF) for the event.
Also, following the briefing, AACR and SITC leaders hosted a live event via the AACR Facebook feed, to answer questions and discuss the day's impact.
The Society for Immunotherapy of Cancer (SITC) strongly opposes the proposed budget cuts to federal scientific research agencies as outlined in the Administration’s recently published fiscal year 2018 budget request.
This proposal calls for a reduction in funding for the National Institutes of Health (NIH) by $5.8 billion or roughly 20% of its total budget. If applied proportionally across NIH, funding for the National Cancer Institute (NCI) would be curtailed by nearly $1 billion. If enacted, these cuts will jeopardize years of progress being made on accelerating cancer research, education, prevention and treatment.
Read more of this SITC statement in Press Releases.
If you have partnership or policy-related questions, please contact SITC staff at SITCExecOffice@sitcancer.org.
Read about how SITC has been active in advocacy, education & lobbying in recent years:
On March 23, 2017, SITC joined 26 other organizations in a letter directed to leaders of the U.S. House of Representatives in strong opposition to the proposed repeal of the indoor tanning tax that was included in the American Health Care Act (AHCA).
To read the full letter, click here.
From Bedside to Bench and Back Again | Boston on September 26-27, 2017 ------------------------------ Joseph Murphy PhD Director Charles River Laboratories Quincy MA ----------------------------
Regarding lymphatic endothelial cell-related cancer and post-transplant recipients. Kaposi's sarcoma-associated herpes virus (KSHV or HHV-8) evades immune killing of tumor cells by relying on its immunomodulatory viral antigens. Organ donors in high seroprevalence ...
There is likely an unpublished cohort of patients throughout the world who were treated with ipilimumab prior to the introduction of nivolumab/ipilimumab combination and achieved an either complete remission or partial remission. These patients then ...
The case report presented here on advanced melanoma, in an elderly patient on page 810, indicates that despite of lack of prior ipilimumab treatment it cannot be excluded that subsequent observed astonishing treatment with nivolumab can partially be due ...
An article of Larking et al published in JCO 2017 showed evidence of the CheckMate 037 in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy, in which they conclude that - and I quote- : "nivolumab treatment after ...
VIEW MORE RESOURCES
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com